Stock Track | PTC Therapeutics Soars 5.28% Pre-Market on Strong Earnings, Promising Pipeline Updates and Bullish Analyst Views

Stock Track

02-28

PTC Therapeutics (PTCT) stock soared 5.28% in the pre-market trading session on Friday, following the release of the company's strong financial results for 2024 and encouraging updates on its promising drug pipeline.

The biopharmaceutical company reported impressive financial performance for the fourth quarter and full year 2024, exceeding expectations. Highlights included:

Q4 revenue of $213 million and full year 2024 revenue of $807 million, surpassing guidance.
Cash position of over $1.1 billion at the end of 2024, further bolstered by a $1 billion upfront payment from Novartis in January 2025.
Strong performance from the company's DMD franchise, which generated $547 million in revenue for the full year 2024.

Additionally, PTC Therapeutics provided promising updates on its drug pipeline, including:

Achieving all clinical and regulatory milestones on schedule in 2024, with four FDA approval applications, one already approved and others under review.
Preparing for multiple potential product launches in 2025, including sepiapterin for PKU and vatiquinone for Friedreich's ataxia, which could significantly enhance their commercial portfolio.
Positive developments in the PTC518 Huntington's disease program, including a global development and commercialization collaboration with Novartis.

Analysts have also expressed optimism about PTC Therapeutics' prospects. William Blair's Sami Corwin and JP Morgan's Eric Joseph both reiterated their "Buy" ratings, citing the company's strong commercial foundation, strategic partnerships, and promising clinical catalysts.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1167719461"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1167719461\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1167719461?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-28 22:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167719461","market":"hk","top_or_hot":-1,"title":"Stock Track | PTC Therapeutics Soars 5.28% Pre-Market on Strong Earnings, Promising Pipeline Updates and Bullish Analyst Views","media":"Stock Track","content":"<p>PTC Therapeutics (PTCT) stock soared 5.28% in the pre-market trading session on Friday, following the release of the company's strong financial results for 2024 and encouraging updates on its promising drug pipeline.</p>\n\n<p>The biopharmaceutical company reported impressive financial performance for the fourth quarter and full year 2024, exceeding expectations. Highlights included:\n<ul>\n<li>Q4 revenue of $213 million and full year 2024 revenue of $807 million, surpassing guidance.</li>\n<li>Cash position of over $1.1 billion at the end of 2024, further bolstered by a $1 billion upfront payment from Novartis in January 2025.</li>\n<li>Strong performance from the company's DMD franchise, which generated $547 million in revenue for the full year 2024.</li>\n</ul>\n</p>\n\n<p>Additionally, PTC Therapeutics provided promising updates on its drug pipeline, including:\n<ul>\n<li>Achieving all clinical and regulatory milestones on schedule in 2024, with four FDA approval applications, one already approved and others under review.</li>\n<li>Preparing for multiple potential product launches in 2025, including sepiapterin for PKU and vatiquinone for Friedreich's ataxia, which could significantly enhance their commercial portfolio.</li>\n<li>Positive developments in the PTC518 Huntington's disease program, including a global development and commercialization collaboration with Novartis.</li>\n</ul>\n</p>\n\n<p>Analysts have also expressed optimism about PTC Therapeutics' prospects. William Blair's Sami Corwin and JP Morgan's Eric Joseph both reiterated their \"Buy\" ratings, citing the company's strong commercial foundation, strategic partnerships, and promising clinical catalysts.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | PTC Therapeutics Soars 5.28% Pre-Market on Strong Earnings, Promising Pipeline Updates and Bullish Analyst Views</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | PTC Therapeutics Soars 5.28% Pre-Market on Strong Earnings, Promising Pipeline Updates and Bullish Analyst Views\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-02-28 22:57</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>PTC Therapeutics (PTCT) stock soared 5.28% in the pre-market trading session on Friday, following the release of the company's strong financial results for 2024 and encouraging updates on its promising drug pipeline.</p>\n\n<p>The biopharmaceutical company reported impressive financial performance for the fourth quarter and full year 2024, exceeding expectations. Highlights included:\n<ul>\n<li>Q4 revenue of $213 million and full year 2024 revenue of $807 million, surpassing guidance.</li>\n<li>Cash position of over $1.1 billion at the end of 2024, further bolstered by a $1 billion upfront payment from Novartis in January 2025.</li>\n<li>Strong performance from the company's DMD franchise, which generated $547 million in revenue for the full year 2024.</li>\n</ul>\n</p>\n\n<p>Additionally, PTC Therapeutics provided promising updates on its drug pipeline, including:\n<ul>\n<li>Achieving all clinical and regulatory milestones on schedule in 2024, with four FDA approval applications, one already approved and others under review.</li>\n<li>Preparing for multiple potential product launches in 2025, including sepiapterin for PKU and vatiquinone for Friedreich's ataxia, which could significantly enhance their commercial portfolio.</li>\n<li>Positive developments in the PTC518 Huntington's disease program, including a global development and commercialization collaboration with Novartis.</li>\n</ul>\n</p>\n\n<p>Analysts have also expressed optimism about PTC Therapeutics' prospects. William Blair's Sami Corwin and JP Morgan's Eric Joseph both reiterated their \"Buy\" ratings, citing the company's strong commercial foundation, strategic partnerships, and promising clinical catalysts.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PTCT","symbol_name":"PTC Therapeutics Inc.","start_time":0,"source_url":"","article_id":"1167719461","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167719461","pubTimestamp":1740754648,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"PTC Therapeutics  stock soared 5.28% in the pre-market trading session on Friday, following the release of the company's strong financial results for 2024 and encouraging updates on its promising drug pipeline.The biopharmaceutical company reported impressive financial performance for the fourth quarter and full year 2024, exceeding expectations. Highlights included:. Q4 revenue of $213 million and full year 2024 revenue of $807 million, surpassing guidance.Cash position of over $1.1 billion at ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PTCT":"PTC Therapeutics Inc."},"translate_title":"股票跟踪PTC Therapeutics盘前飙升5.28%，原因是强劲的盈利、充满希望的产品线更新和看涨的分析师观点","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTCT":1},"content_text":"PTC Therapeutics (PTCT) stock soared 5.28% in the pre-market trading session on Friday, following the release of the company's strong financial results for 2024 and encouraging updates on its promising drug pipeline.\nThe biopharmaceutical company reported impressive financial performance for the fourth quarter and full year 2024, exceeding expectations. Highlights included:\n\nQ4 revenue of $213 million and full year 2024 revenue of $807 million, surpassing guidance.\nCash position of over $1.1 billion at the end of 2024, further bolstered by a $1 billion upfront payment from Novartis in January 2025.\nStrong performance from the company's DMD franchise, which generated $547 million in revenue for the full year 2024.\n\nAdditionally, PTC Therapeutics provided promising updates on its drug pipeline, including:\n\nAchieving all clinical and regulatory milestones on schedule in 2024, with four FDA approval applications, one already approved and others under review.\nPreparing for multiple potential product launches in 2025, including sepiapterin for PKU and vatiquinone for Friedreich's ataxia, which could significantly enhance their commercial portfolio.\nPositive developments in the PTC518 Huntington's disease program, including a global development and commercialization collaboration with Novartis.\n\nAnalysts have also expressed optimism about PTC Therapeutics' prospects. William Blair's Sami Corwin and JP Morgan's Eric Joseph both reiterated their \"Buy\" ratings, citing the company's strong commercial foundation, strategic partnerships, and promising clinical catalysts.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}